Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

2.04USD
8:16pm BST
Change (% chg)

$0.05 (+2.51%)
Prev Close
$1.99
Open
$2.10
Day's High
$2.10
Day's Low
$2.01
Volume
118,047
Avg. Vol
71,306
52-wk High
$2.65
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR DEVELOPMENT OF AV-101 AS A NON-OPIOID TREATMENT FOR NEUROPATHIC PAIN.VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR DEVELOPMENT OF AV-101 AS A NON-OPIOID TREATMENT FOR NEUROPATHIC PAIN.  Full Article

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Vistagen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​.  Full Article

Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Intracoastal Capital Llc::REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>>: AS OF DEC 13 - SEC FILING.  Full Article

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

VistaGen Therapeutics reports Q3 loss per share $0.34
Monday, 13 Feb 2017 

VistaGen Therapeutics Inc : VistaGen Therapeutics reports fiscal third quarter 2017 financial results and provides corporate update .Q3 loss per share $0.34.  Full Article